Application of saikoside d in preparation of anti-hepatic fibrosis disease drugs

An anti-liver fibrosis and saikosaponin technology, applied in the field of saikosaponin d (SS-d), can solve the problem of lack of anti-liver fibrosis drugs, reduce the generation of oxygen free radicals, inhibit activation, and improve resistance Effects of liver fibrosis

Inactive Publication Date: 2014-01-01
SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Liver fibrosis is a pre-disease of liver cirrhosis and is a reversible lesion. However, there is still a lack of effective anti-hepatic fibrosis drugs. Therefore, finding effective drugs to overcome liver fibrosis has broad application prospects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of saikoside d in preparation of anti-hepatic fibrosis disease drugs
  • Application of saikoside d in preparation of anti-hepatic fibrosis disease drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The specific implementation manners provided by the present invention will be described in detail below with reference to the accompanying drawings.

[0015] 1 Materials and methods

[0016] 1.1 Drugs and reagents

[0017] Saikosaponin d (SS-d) purchased from White China Institute of Chinese Medicine (purity> 98%), colchicine (Col) purchased Baikunming Pharmaceutical Co., Ltd., Tri-zol purchased White Molecular Probe Company, and fluorescent quantitative PCR kit purchased Baitiangen Biochemical Technology (Beijing) Co., Ltd., TGF-β1 , GAPDH antibody was purchased from Santa Cruz, USA.

[0018] 1.2 Establishment of experimental animals, grouping and immune rat liver fibrosis model

[0019] 60 Wistar rats, half male and half, weighing (140±15) g, were purchased from Shanghai Experimental Animal Center. All rats were fed in separate cages for clean animals in a ventilated and quiet environment. 60 Wistar rats were randomly divided into 6 groups, normal control group (n=10), model ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of saikoside d in preparation of anti-hepatic fibrosis disease drugs, and belongs to the technical field of medicines. The invention aims to provide pharmacological activities exhibited by the saikoside d in treatment of hepatic fibrosis symptoms and related mechanisms. The saikoside d has a good anti-hepatic fibrosis effect, and the action mechanisms may be related with improvement of activities of superoxide dismutase, reduction of generation of oxyradical and inhibition of activation of TGF-beta 1 (transforming growth factor) signaling pathway.

Description

Technical field [0001] The present invention relates to the use of saikosaponin d (SS-d), in particular to the use in the preparation of drugs for treating liver fibrosis. Background technique [0002] Compound SS-d belongs to pentacyclic triterpenoid oligopan derivatives, and its structural formula is [0003] The molecular formula of this compound is C 42 H 68 O 13 , The molecular weight is 780.98, white powder. The compound can be obtained by extracting from the root of Bupleurum, and is known to have anti-inflammatory, anti-tumor, anti-kidney and liver fibrosis pharmacological effects. [0004] Liver fibrosis is a pathological process in which various pathogenic factors cause abnormal proliferation of connective tissue in the liver, and excessive precipitation of extracellular matrix proteins to form fibrous scars. It is the final result of many chronic liver diseases. Further development often leads to cirrhosis and liver function. Failure or portal hypertension. Liver fibr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16
Inventor 李勇任建琳王建胡晔王鑫陶智会
Owner SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap